In three European countries
Venus Remedies announced that its wholly owned subsidiary has entered into a distribution-cum-outsourcing agreement with Mylan for marketing its generic broad-spectrum antibiotic, meropenem, in three European countries.The deal with Mylan will enable Venus Remedies to market meropenem in Denmark, Sweden and Finland for a period of five years.
Under the non-exclusive marketing agreement, Venus will manufacture the drug at its Baddi facility, which recently got a renewed European Union Good Manufacturing Practices (GMP) certification, while the batch release and logistics will be handled by its Germany facility Venus Pharma GmbH.
Powered by Capital Market - Live News
